Relationship between the changes of biochemical markes of bone turnover and osteoporosis in male patients with type 2 diabetes

doi:10.3877/cma.j.issn.2095-5820.2014.01.010

Abstract

Abstract:

Objective

To investigate the relationship of diabetic male patients with osteoporosis and the bone turnover markers.

Methods

Dual-energy X-ray absorptiometry was used to measure lumbar spine bone mineral density, 102 diabetic patients were divided into osteoporosis group (50 cases) and nonosteoporosis group (52 cases). The levels of total procollagen type I amino-terminal propeptide (TPINP), β-C-terminal telopeptide of type I collagen (β-CTX), the N end osteocalcin (N-MID), the 25(hydroxyl)vitamin D3[25-(OH) VD3], serum calcium (Ca), serum phosphorus (P), glycosylated hemoglobin (HbA1c), creatinine and other biochemical indicators were detected to analyze the related cause of the risk factors for osteoporosis in patients with T2DM.

Results

The values of osteoporosis in lumbar spine bone mineral density (0.91±0.10, 0.96±0.12,1.04±0.10, 1.03±0.10, 0.98±0.08) were decreased as compared with the non-osteoporosis group (1.21±0.12,1.30±0.13, 1.37±0.16, 1.39±0.14, 1.33±0.15, t=13.688, 13.710, 12.542, 14.988, 14.566, P＜0.01). The TPINP, β-CTX, HbA1c in the osteoporosis group[(49.16±17.94) μg/L, (615.63±131.24) ng/L, (9.81±2.37)%]were higher than the non-osteoporosis group [(35.44±2.97) μg/L, (532.00±119.23) ng/L, (8.22±0.41)%, t=-4.412,-3.371, -4.687, P＜0.01], 25-(OH)VD3 in osteoporosis group was lower than the non-osteoporosis group[(17.23±4.88) μg/L vs (20.02±5.53) μg/L; t=2.696, P＜0.01]. Correlation analysis showed T-PINP, β-CTX were negatively correlated with BMD of spine in T2DM patients with osteoporosis (r=-0.720, -0.615, -0.768, P＜0.01)and 25-(OH)VD3 was positively correlated with BMD of spine (r=0.808, P＜0.01).

Conclusions

The spine BMD in T2DM patients is decreased to some degree. The application of TPINP, β-CTX, 25-(OH) VD3 and HbA1c are helpful for the early diagnosis of osteoporosis in patients with T2DM.

Key words: Diabetes mellitus, type 2, Osteoporosis, Bone density, Markers of bone turnover

Qipeng Xie, Dingxing Ye, Huaikai Wen, Xiangyang Li. Relationship between the changes of biochemical markes of bone turnover and osteoporosis in male patients with type 2 diabetes[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2014, 02(01): 51-54.

/ Save 0 / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2014.01.010

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2014/V02/I01/51

Figures/Tables 4

References 10

1	刘忠厚. 骨质疏松学[M]. 北京：科学技术出版社，1988,142-144.
2	Saller A, Maggi S, Romanato G, et al. Diabetes and osteoprosis[J].Aging Clin Exp res, 2008, 20(4): 280-289.
3	Hofbauer LC, Brueck CC, Singh SK, et al. Osteoporosis in patients with diabetes mellitus[J]. J boneMiner Res, 2007, 22(9): 1317-1328.
4	Clowes JA, Peel NF, Eastell R. The impact of monitor on adherence and persistence with antiresorptive treatment for postlnenopausal osteoporosis:a randomized controlled trial[J]. J Clin Endocrinol Metab,2004, 89(3): 1117-1123.
5	Clowes JA, Eastell R. The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk[J]. Baillieres Best Pract Res Clin Endocrinol Metab, 2000, 14(2): 213-232.
6	Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum[J]. Clin Biochem，2012, 45(12): 920-927.
7	Herrmann M，Seibel M. The amino and carboxyterminal cross-linked telopetides of collagen type I , NTX-I and CTX-I: a comparative review[J]. Clinl Chim Acta, 2008, 393(2): 57-75.
8	Garnero P. Biomarkers for Osteoporosis Management[J]. Mol Diagn Ther, 2008, 12(3): 157-170.
9	孙胜花, 云武, 宋钦华, 等. 43例2型糖尿病患者骨密度和骨代谢的研究[J]. 中国热带医学, 2006, 6(9): 1635-1636.
10	Melton LJ 3rd, leibson CL, Achenbach SJ, et al. Fracture risk in type 2 diabetes:update of a population-based study[J]. J Bone Miner Res,2008, 23(8): 1334-1342.

组别	例数	N-MID（μg/L）	T-PINP（μg/L）	β-CTX（ng/L）	25-（OH）VD3（μg/L）	血Ca²⁺（mmol/L）	血P（mmol/L）	肌酐（μmol/L）	HbA1c（%）
骨质疏松组	50	17.21±3.39	49.16±17.94	615.63±131.24	17.23±4.88	2.39±0.21	1.19±0.32	66.28±15.13	9.81±2.37
非骨质疏松组	52	16.76±3.47	35.44±2.97	532.00±119.23	20.02±5.53	2.41±0.10	1.24±0.21	67.47±15.64	8.22±0.41
t值		-0.669	-4.412	-3.371	2.696	0.436	0.987	0.387	-4.687
P值		0.505	0.000	0.010	0.008	0.665	0.326	0.699	0.000

组别	例数	N-MID（μg/L）	T-PINP（μg/L）	β-CTX（ng/L）	25-（OH）VD3（μg/L）	血Ca²⁺（mmol/L）	血P（mmol/L）	肌酐（μmol/L）	HbA1c（%）
骨质疏松组	50	17.21±3.39	49.16±17.94	615.63±131.24	17.23±4.88	2.39±0.21	1.19±0.32	66.28±15.13	9.81±2.37
非骨质疏松组	52	16.76±3.47	35.44±2.97	532.00±119.23	20.02±5.53	2.41±0.10	1.24±0.21	67.47±15.64	8.22±0.41
t值		-0.669	-4.412	-3.371	2.696	0.436	0.987	0.387	-4.687
P值		0.505	0.000	0.010	0.008	0.665	0.326	0.699	0.000

组别	例数	N-MID（μg/L）	T-PINP（μg/L）	β-CTX（ng/L）	25-（OH）VD3（μg/L）
无并发症组	20	16.88±1.75	40.72±10.56	582.62±76.59	18.97±2.56
有并发症组	30	17.83±2.34	52.84±12.62	626.15±56.45	15.68±2.24
t值		1.548	3.543	2.314	4.805
P值		0.128	0.001	0.025	0.000

组别	例数	N-MID（μg/L）	T-PINP（μg/L）	β-CTX（ng/L）	25-（OH）VD3（μg/L）
无并发症组	20	16.88±1.75	40.72±10.56	582.62±76.59	18.97±2.56
有并发症组	30	17.83±2.34	52.84±12.62	626.15±56.45	15.68±2.24
t值		1.548	3.543	2.314	4.805
P值		0.128	0.001	0.025	0.000

骨转换指标	脊柱骨密度
骨转换指标	r值	P值
N-MID	-0.010	0.943
T-PINP	-0.720	0.000
β-CTX	-0.615	0.000
25-(OH)VD3	0.808	0.000
血Ca²⁺	0.191	0.184
血P	-0.175	0.225
肌酐	0.106	0.463
HbA1c	-0.768	0.000

Please choose a citation manager

Content to export